Kiniksa Pharmaceuticals International, plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Kiniksa Pharmaceuticals International, plc (KNSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.60 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-02-28
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $2.60M, a 18.17% increase from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $2.20M, a 65.64% decline from fiscal 2021.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $6.39M, a 65.02% decline from fiscal 2020.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $18.27M, a 928.77% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2023-12-31 | $2.60M 10-K · filed 2024-02-28 |
| 2022-12-31 | $2.20M 10-K · filed 2024-02-28 |
| 2021-12-31 | $6.39M 10-K · filed 2024-02-28 |
| 2020-12-31 | $18.27M 10-K · filed 2023-03-02 |
| 2019-12-31 | $1.78M 10-K · filed 2022-02-24 |